Related Experiment Video
Updated: Sep 5, 2025

Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease
Published on: February 3, 2012
ACLY and CKD: A Mendelian Randomization Analysis
Pedrum Mohammadi-Shemirani1,2,3, Michael Chong1,2,3, Nicolas Perrot1
1Department of Biomarkers and Genetics, Population Health Research Institute, Hamilton, Ontario, Canada.
Introduction:
Adenosine triphosphate-citrate lyase (ACLY) inhibition is a therapeutic strategy under investigation for atherosclerotic cardiovascular disease, nonalcoholic steatohepatitis, and metabolic syndrome. Mouse models suggest that ACLY inhibition could reduce inflammation and kidney fibrosis. Genetic analysis of ACLY in chronic kidney disease (CKD) has not been performed.
Methods:
We constructed a genetic instrument by selecting variants associated with ACLY expression in the expression quantitative trait loci genetics consortium (eQTLGen) from blood samples from 31,684 participants. In a 2-sample Mendelian randomization analysis, we evaluated the effect of genetically predicted ACLY expression on the risk of CKD, estimated glomerular filtration rate (eGFR), and albumin-to-creatinine ratio (ACR) using the CKD Genetics (CKDGen) consortium, UK Biobank, and the Finnish Genetics (FinnGen) consortium totaling 66,396 CKD cases and 958,517 controls.
Results:
ACLY is constitutively expressed in all cell types including in whole blood. The genetic instrument included 13 variants and explained 1.5% of the variation in whole blood ACLY gene expression. A 34% reduction in ACLY expression score was associated with a 0.04 mmol/l reduced low-density lipoprotein (LDL) cholesterol (P = 3.4 × 10-4) and a 9% reduced risk of CKD (stages 3, 4, 5, dialysis, or eGFR < 60 ml/min per 1.73 m2) (odds ratio [OR] = 0.91, 95% CI: 0.85-0.98, P = 0.008), but no association was observed with either eGFR or ACR.
Conclusion:
Mendelian randomization analyses revealed that genetically reduced ACLY expression was associated with reduced risk of CKD but had no effect on either eGFR or ACR. Further evaluation of ACLY in kidney disease is warranted.
Insights
Adenosine triphosphate-citrate lyase (ACLY) inhibition may reduce chronic kidney disease (CKD) risk. Genetically reduced ACLY expression was linked to a lower CKD risk, but not estimated glomerular filtration rate or albumin-to-creatinine ratio.
Area of Science:
- Biochemistry
- Genetics
- Nephrology
Background:
- Adenosine triphosphate-citrate lyase (ACLY) is a therapeutic target for metabolic diseases.
- ACLY inhibition shows potential in reducing inflammation and kidney fibrosis in mouse models.
- Genetic analysis of ACLY in chronic kidney disease (CKD) has been lacking.
Purpose of the Study:
- To investigate the effect of genetically predicted Adenosine triphosphate-citrate lyase (ACLY) expression on the risk of chronic kidney disease (CKD).
- To evaluate the association between ACLY expression and kidney function markers, including estimated glomerular filtration rate (eGFR) and albumin-to-creatinine ratio (ACR).
Main Methods:
- Constructed a genetic instrument for ACLY expression using 13 variants from the eQTLGen consortium.
- Performed a 2-sample Mendelian randomization analysis using data from CKDGen, UK Biobank, and FinnGen.
- Evaluated the effect of genetically predicted ACLY expression on CKD risk, eGFR, and ACR in 66,396 CKD cases and 958,517 controls.
Main Results:
- Genetically reduced ACLY expression was associated with a 9% reduced risk of CKD.
- A 34% reduction in ACLY expression score correlated with lower LDL cholesterol.
- No significant association was found between genetically reduced ACLY expression and eGFR or ACR.
Conclusions:
- Genetically reduced Adenosine triphosphate-citrate lyase (ACLY) expression is associated with a decreased risk of chronic kidney disease (CKD).
- ACLY does not appear to influence estimated glomerular filtration rate (eGFR) or albumin-to-creatinine ratio (ACR).
- Further research into ACLY's role in kidney disease is warranted.
More Related Videos
08:46Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
07:35Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Related Concept Videos
Randomized Experiments
Simple randomization
Simple...
Mechanistic Models: Compartment Models in Individual and Population Analysis
Determination of Renal Drug Clearance: Graphical and Midpoint Methods
The graphical method involves plotting the rate of drug excretion in urine against the plasma drug concentration. By analyzing the graph, the clearance can be calculated and obtained. Drugs rapidly excreted by the kidneys exhibit a...
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Chi-square Analysis
The chi-square test was developed by Pearson in 1990.
The first step of performing a Chi-square analysis is to establish a null hypothesis, which assumes that there is no real...
Acute Kidney Injury IV: Diagnostic Studies and Prevention